VivoSeq
Other

Biosimilarity

0

Pipeline Programs↗

2

Active Trials↗

4

Companies Involved↗

Biosimilarity is an early-stage landscape with 0 programs across 4 companies. The most active players are Gan and Lee Pharmaceuticals, USA, Gan & Lee Pharmaceuticals., Coherus Oncology, Inc..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Gan and Lee Pharmaceuticals, USA

0 programs

PreclinicalG

Gan & Lee Pharmaceuticals.

0 programs

PreclinicalC

Coherus Oncology, Inc.

0 programs

PreclinicalA

Amphastar Pharmaceuticals, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

9

clinical trials

Completed7 · 78%
Not yet recruiting2 · 22%

Clinical Trials

Trial Activity

9 trials

A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male Subjects
Not yet recruiting·GGan & Lee Pharmaceuticals.·Phase 1·NCT07334496·198 enrolled
Biosimilarity Study of Subcutaneous Filgrastim in Healthy Volunteers
Not yet recruiting·MMegalabs·Phase 1·NCT04958772·100 enrolled
PK/PD Biosimilarity Study of Gan & Lee Insulin Lispro Injection vs. EU and US Humalog® in Healthy Males
Completed·GGan and Lee Pharmaceuticals, USA·Phase 1·NCT04235439·36 enrolled
Biosimilarity Study of IM Injection of Human Chorionic Gonadotrophin After Parenteral Administration of Treatment A TEST Product Epifasi 5000 I.U. Ampoules (EIPICO PHARMA, EGYPT) and Treatment B REFERENCE Product Pregnyl 5000 I.U. Ampoules (Baxter Pharmaceutical Solutions for Organon, USA).
Completed·GGenuine Research Center, Egypt·Phase 4·NCT04605107·60 enrolled
Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221 (GEROPHARM LLC, Russia) and Ozempic®.
Completed·GGeropharm·Phase 1·NCT06497049·120 enrolled
Biosimilarity Study of Subcutaneous Pegfilgrastim in Healthy Volunteers
Completed·MMegalabs·Phase 1·NCT04873765·72 enrolled
A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers
Completed·LLannett Company, Inc.·Phase 1·NCT05248841·104 enrolled
Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)
Completed·CCoherus Oncology, Inc.·Phase 1·NCT02385851·116 enrolled
Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers
Completed·AAmphastar Pharmaceuticals, Inc.·Phase 2/3·NCT05539872·69 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)